Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007721 | 0.91 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11TAS2R14 | |
| SCHEMBL5010659 | 0.88 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11TAS2R14 | |
| SCHEMBL5010753 | 0.88 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5008506 | 0.88 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5005515 | 0.88 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11TAS2R14 | |
| SCHEMBL28757654 | 0.86 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11GFER | |
| SCHEMBL5008519 | 0.86 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3864506 | 0.85 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL5008441 | 0.84 | MAPT (0.47) | TAS2R14GFERMAPT | |
| SCHEMBL14600217 | 0.84 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | claimed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | claimed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPK14 1938/4885MAPK13 885/4885MAPK12 1488/4885 |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPK14 1938/4885MAPK13 885/4885MAPK12 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.